Weight Loss Simulator for GLP-1 users.
See how building habits can change a weight curve on medication, using published clinical averages. For information only, not a prediction or medical advice.
Toggle to compare the two curves
Frequently asked questions.
Clinical trials show average weight loss of about 15% of body weight on semaglutide (Ozempic/Wegovy) and about 20% on tirzepatide (Mounjaro/Zepbound) over 12 to 18 months. Individual results vary based on starting weight, diet, activity, and other factors. This is general information, not a prediction for any individual.
It describes two trajectories. A V-shape is when people lose weight on medication but regain most of it after stopping. An L-shape is when people build durable habits during treatment, so their weight tends to stay down after tapering off.
Studies suggest a large share of lost weight is regained within a year of stopping if no lifestyle changes are maintained. People who build sustainable nutrition and movement habits during treatment tend to maintain more of their progress.
Build habits while the medication makes it easier: aim for your protein goals, keep a regular movement routine, track your meals, and taper gradually with your provider rather than stopping abruptly. A tool like Phaze can help you build these habits consistently.
Build habits that outlast the medication.
Phaze helps you build nutrition, movement, and tracking habits while the medication makes it easier, so the changes can stick. Free to start.
Get Phaze FreeThis simulator is for information only. It illustrates patterns based on published clinical averages and is not a prediction of your results or medical advice. Individual results vary significantly. Always follow your healthcare provider's guidance before changing your medication or treatment plan.